Literature DB >> 11970966

Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation.

Edward Y Woo1, Heidi Yeh, Christina S Chu, Katia Schlienger, Richard G Carroll, James L Riley, Larry R Kaiser, Carl H June.   

Abstract

Active suppression by T regulatory cells plays an important role in the down-regulation of T cell responses to foreign and self-Ags. Thus far, the potential role of CD4(+)CD25(+) T cells in human tumors has not been reported. In this work we show that lung tumors contain large numbers of these cells and that they have constitutive high-level expression of CD152 (CTLA-4). Furthermore, the CD4(+)CD25(+) T cells mediate potent inhibition of autologous T cell proliferation. Finally, regulatory T cells from patient tumors failed to inhibit the proliferation of allogeneic T cells. Together these results suggest that the CD4(+)CD25(+) T cells found in lung tumors selectively inhibit the host immune response and therefore could contribute to the progression of lung cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11970966     DOI: 10.4049/jimmunol.168.9.4272

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  189 in total

1.  Increased hepatitis C virus (HCV)-specific CD4+CD25+ regulatory T lymphocytes and reduced HCV-specific CD4+ T cell response in HCV-infected patients with normal versus abnormal alanine aminotransferase levels.

Authors:  F Bolacchi; A Sinistro; C Ciaprini; F Demin; M Capozzi; F C Carducci; C M J Drapeau; G Rocchi; A Bergamini
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

Review 2.  Making room for T cells.

Authors:  Gabriel N Maine; James J Mulé
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

Review 3.  Lung cancer vaccines.

Authors:  Ronan J Kelly; Giuseppe Giaccone
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

Review 4.  Immunotherapy for non-small cell lung cancer: current concepts and clinical trials.

Authors:  Marissa Mayor; Neng Yang; Daniel Sterman; David R Jones; Prasad S Adusumilli
Journal:  Eur J Cardiothorac Surg       Date:  2015-10-29       Impact factor: 4.191

5.  Inhibition of breast cancer metastasis by resveratrol-mediated inactivation of tumor-evoked regulatory B cells.

Authors:  Catalina Lee-Chang; Monica Bodogai; Alejandro Martin-Montalvo; Katarzyna Wejksza; Mitesh Sanghvi; Ruin Moaddel; Rafael de Cabo; Arya Biragyn
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

Review 6.  CD25+ CD4+ regulatory T-cells in cancer.

Authors:  David C Linehan; Peter S Goedegebuure
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 7.  Tregs and rethinking cancer immunotherapy.

Authors:  Tyler J Curiel
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 8.  The role of B7 family molecules in hematologic malignancy.

Authors:  Paul Greaves; John G Gribben
Journal:  Blood       Date:  2012-12-06       Impact factor: 22.113

9.  Adenocarcinoma contains more immune tolerance regulatory t-cell lymphocytes (versus squamous carcinoma) in non-small-cell lung cancer.

Authors:  Candice C Black; Mary Jo Turk; Konstantin Dragnev; James R Rigas
Journal:  Lung       Date:  2013-03-15       Impact factor: 2.584

Review 10.  Overview of a HLA-Ig based "Lego-like system" for T cell monitoring, modulation and expansion.

Authors:  Mathias Oelke; Jonathan P Schneck
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.